Magda Marquet

Acurion is revolutionizing frontline cancer care by equipping oncologists with critical genomic activity insights to get cancer patients onto the right treatments faster. The companys mission is to accelerate the translation of its life-saving AI technology into the clinical arena to make a real, immediate and profound difference in therapy for patients worldwide. Dedicated to improving patient outcomes, Acurion collaborates with leading research institutions, patient advocacy groups, and industry partners to advance precision oncology. Please visit www.acurionhealth.com to learn more.

The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.

Micronoma is the first cancer-detection company using liquid biopsy technology to detect and predict cancer by interrogating the microbial signal with clinical-grade accuracy at an early stage of the disease. Micronoma was founded by leaders in microbiome research, and committed to improving the lives of all involved in cancer diagnosis. The company started in 2019 and is headquartered in San Diego, California.

The Pelican Expression Technology® Platform is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well-suited for complex, large-scale protein production where traditional systems are not suitable. Multiple global manufacturers have demonstrated consistent success with the platform and the technology is currently out-licensed for numerous commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. Partners seek the platform as it can contribute significant value to biopharmaceutical development programs by reducing development timelines and costs for manufacturing therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increasing structural complexities, the Pelican Expression Technology Platform is well positioned to meet these growing needs as the most comprehensive broadly available protein production platform in the industry.

Arcturus Therapeutics is a global late stage-clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

Senté is an emerging medical-grade skincare company with products recommended and dispensed by several hundred physician offices across the US, as well as online directly to customers. Senté is the first and only company to successfully develop a version of Heparan Sulfate—a natural molecule our bodies use to renew damaged, inflamed skin—and infuse it into skincare products. Our mission is to give back the confidence that comes from healthy skin. Confidence is freedom, and Senté is providing the science to prove it’s possible to achieve both.

Acurion is revolutionizing frontline cancer care by equipping oncologists with critical genomic activity insights to get cancer patients onto the right treatments faster. The companys mission is to accelerate the translation of its life-saving AI technology into the clinical arena to make a real, immediate and profound difference in therapy for patients worldwide. Dedicated to improving patient outcomes, Acurion collaborates with leading research institutions, patient advocacy groups, and industry partners to advance precision oncology. Please visit www.acurionhealth.com to learn more.

AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulating antibodies, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases: rosnilimab, our PD-1 agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; and ANB032, our BTLA agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases. AnaptysBio has developed two cytokine antagonists available for outlicensing: imsidolimab, an anti-IL-36r antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. AnaptysBio has also discovered antibodies licensed to GSK in a financial collaboration for immune-oncology, including an anti-PD-1 antagonist (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist (cobolimab, GSK4069889) and an anti-LAG-3 antagonist (GSK4074386).

The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.

Micronoma is the first cancer-detection company using liquid biopsy technology to detect and predict cancer by interrogating the microbial signal with clinical-grade accuracy at an early stage of the disease. Micronoma was founded by leaders in microbiome research, and committed to improving the lives of all involved in cancer diagnosis. The company started in 2019 and is headquartered in San Diego, California.

The Pelican Expression Technology® Platform is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well-suited for complex, large-scale protein production where traditional systems are not suitable. Multiple global manufacturers have demonstrated consistent success with the platform and the technology is currently out-licensed for numerous commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. Partners seek the platform as it can contribute significant value to biopharmaceutical development programs by reducing development timelines and costs for manufacturing therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increasing structural complexities, the Pelican Expression Technology Platform is well positioned to meet these growing needs as the most comprehensive broadly available protein production platform in the industry.